Saturday, 18 December 2010
Seroxat Litigation - Report of the Committee on Safety of Medicines Expert Working Group on SSRI Antidepressants, 2004 - ‘Suicidal Behaviour in association with SSRI’
The previous and following excerpt of the Committee on Safety of Medicines (CSM) Expert Working Group (EWG) report “On the Safety of Selective Serotonin Reuptake Inhibitor Antidepressants” published December 2004 shows that the issue of withdrawal, dependence, suicidal and aggressive behaviour in associated with SSRI fluoxetine (Prozac) was under review with some gravity by the UK Medicine Control Agency (MCA) and CSM from 1990, referenced in MCA / CSM 'Current Problems in Pharmacovigilance', June 1992.
The review widened encompassing newer SSRI drugs when approved and licensed, close monitoring of spontaneous adverse drug reports (ADRs) lead to “a UK exercise in 1998 -2000 to develop harmonised safety information for all SSRIs”, acknowledging that all drugs in the class induced similar ADRs and side effects, and Dr David Healy’s 1999 publication ‘A Failure to Warn’ raised the level of concern in the issue of suicide and introduced SSRI induced akathisia - the now acknowledged precursor to suicidal ideation and action.
Dr David Healy was in correspondence with the MCA by November 4th 1999 about the suicide issue and voicing concerns about the number of SSRIs being prescribed to children and adolescence,
http://the-uk-seroxat-litigation-chronicles.blogspot.co.uk/2010/12/seroxat-litigation-report-of-committee.html
Seroxat Litigation - Report of the Committee on Safety of Medicines Expert Working Group on SSRI Antidepressants, 2004 - ‘Suicidal Behaviour in association with SSRI’
The previous and following excerpt of the Committee on Safety of Medicines (CSM) Expert Working Group (EWG) report “On the Safety of Selective Serotonin Reuptake Inhibitor Antidepressants” published December 2004 shows that the issue of withdrawal, dependence, suicidal and aggressive behaviour in associated with SSRI fluoxetine (Prozac) was under review with some gravity by the UK Medicine Control Agency (MCA) and CSM from 1990, referenced in MCA / CSM 'Current Problems in Pharmacovigilance', June 1992.
The review widened encompassing newer SSRI drugs when approved and licensed, close monitoring of spontaneous adverse drug reports (ADRs) lead to “a UK exercise in 1998 -2000 to develop harmonised safety information for all SSRIs”, acknowledging that all drugs in the class induced similar ADRs and side effects, and Dr David Healy’s 1999 publication ‘A Failure to Warn’ raised the level of concern in the issue of suicide and introduced SSRI induced akathisia - the now acknowledged precursor to suicidal ideation and action.
Dr David Healy was in correspondence with the MCA by November 4th 1999 about the suicide issue and voicing concerns about the number of SSRIs being prescribed to children and adolescence,
http://the-uk-seroxat-litigation-chronicles.blogspot.co.uk/2010/12/seroxat-litigation-report-of-committee.html
No comments:
Post a Comment
Note: only a member of this blog may post a comment.